Sponsors (4)
This bill aims to make U.S. medical supply chains more resilient and faster by diversifying suppliers, harmonizing regulations, and increasing oversight and enforcement, but it trades off higher costs, potential harm to some domestic manufacturers, regulatory/safety risks from greater foreign reliance, and added political and administrative complexity.
Hospitals, health systems, and patients (especially those with chronic conditions) would face fewer shortages and more reliable access to critical medical supplies during emergencies because the U.S. would diversify suppliers, exempt certain medical goods from trade restrictions, and prioritize reliable partners.
Hospitals, patients, and medical suppliers would get faster access to imports and clearer regulatory paths because the bill promotes regulatory harmonization, mutual recognition, and clearer statutory definitions, shortening time‑to‑market and reducing import delays and compliance uncertainty.
U.S. manufacturers and small businesses in the life‑science and medical goods sectors could receive increased investment, support, and market opportunities to expand domestic production capacity, potentially creating jobs and strengthening supply resilience.
Hospitals, taxpayers, and patients could face higher costs because diversifying toward U.S. or allied suppliers, stronger intellectual‑property protections, or other sourcing shifts may be more expensive than current suppliers and duty changes could raise prices.
Patients and hospitals could face increased safety and quality risks if regulatory harmonization or reliance on foreign authorizations reduces independent U.S. scrutiny of medical products.
U.S. manufacturers and small businesses may be harmed by increased foreign competition and reduced incentives for domestic production if duty reductions and broader market access shift sourcing abroad.
Based on analysis of 7 sections of legislative text.
Introduced March 12, 2025 by Thomas Roland Tillis · Last progress March 12, 2025
Authorizes the President to negotiate and implement "trusted trade partner" agreements with foreign countries to change duties, streamline cross‑border movement, and harmonize regulatory rules for medical devices, pharmaceuticals, and their inputs to strengthen U.S. medical supply‑chain resilience. It requires specific partner commitments, periodic reporting to Congress, mandatory congressional notice and a review/disapproval process before agreements take effect, and a monitoring and remediation process for partner noncompliance.